You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

ATV-1601 Targeted Therapy for Stage III-IV Breast Cancer With an AKT1 E17K Mutation

A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of ATV-1601 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with an AKT1 E17K mutation and no standard treatment options available. You must not have mutations in KRAS, NRAS, HRAS, or BRAF or uncontrolled, symptomatic brain metastases. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups depending on your breast cancer subtype: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: HR- Breast Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATV-1601, by mouth, up to 4 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: HR+ Breast Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATV-1601, by mouth, up to 4 years</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, up to 4 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATV-1601 targets the E17K mutation in the AKT1 gene to stop cancer cells from growing fast.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07038369' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://atavistikbio.com/programs/#pipelineintro' target='_blank'>Atavistik Bio: ATV-1601</a> </li></ul>
1

ATV-1601 Targeted Therapy for Stage III-IV Breast Cancer With an AKT1 E17K Mutation

A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors
Icon

Nearest Location:
348 miles
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07038369

Icon

Phase I

HELP GUIDE
HELP GUIDE